HIMS stock plunged 26% as Novo Nordisk ended collaboration over concerns about knockoff sales of weight-loss drug Wegovy. Novo accused Hims & Hers Health of deceptive promotion and selling illegitimate versions of Wegovy. Hims stock had soared after the deal in April. Novo will work with other telehealth companies for Wegovy access. Hims faces challenges filling the gap left by the scrapped Novo deal.
Read more@
